Albireo Pharma Inc (NASDAQ:ALBO)

32.95
Delayed Data
As of 4:00pm ET
 +0.15 / +0.46%
Today’s Change
15.31
Today|||52-Week Range
39.87
+28.71%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$368.4M

Company Description

Albireo Pharma, Inc. is a pharmaceutical company engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions. Its product pipeline includes A4250, developed for children with chronic cholestasis; and A3384 designed to deliver cholestyramine directly to the colon. The company was founded by Jan Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Contact Information

Albireo Pharma, Inc.
10 Post Office Square
Boston Massachusetts 02109
P:(857) 254-5555
Investor Relations:

Employees

Shareholders

Other institutional37.79%
Individual stakeholders27.66%
Mutual fund holders12.97%

Top Executives

Ronald H. W. CooperPresident & Chief Executive Officer
Jan Peter MattssonChief Operating Officer
Mike GutchCFO, Director & Chief Business Officer
Paresh N. SoniChief Medical & Scientific Officer
Alan Seth KrasnerChief Medical Officer